Delving into the Latest Updates on Chia Tai Pharmaceutical (Qingdao) Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

主要目的：评价 BG136 在晚期结直肠癌受试者中的初步抗肿瘤疗效。次要目的：评价 BG136 在晚期结直肠癌受试者中的安全性；评价 BG136 在晚期结直肠癌受试者中的药代动力学（PK）特征；评价 BG136 在晚期结直肠癌受试者中的药效学（PD）特征；评价 BG136 在晚期结直肠癌受试者的免疫原性。

[Translation]

Primary objective: To evaluate the preliminary anti-tumor efficacy of BG136 in subjects with advanced colorectal cancer. Secondary objectives: To evaluate the safety of BG136 in subjects with advanced colorectal cancer; To evaluate the pharmacokinetic (PK) characteristics of BG136 in subjects with advanced colorectal cancer; To evaluate the pharmacodynamic (PD) characteristics of BG136 in subjects with advanced colorectal cancer; To evaluate the immunogenicity of BG136 in subjects with advanced colorectal cancer.

Start Date21 Apr 2025

Sponsor / Collaborator

Ocean University of China

[+2]

CTR20250369

/ CompletedNot Applicable

罗沙司他胶囊在健康受试者中的单中心、开放、随机、单剂量、两序列、空腹及餐后两周期、双交叉设计的生物等效性研究.

[Translation] A single-center, open-label, randomized, single-dose, two-sequence, two-period fasting and two-feeding, double-crossover bioequivalence study of roxadustat capsules in healthy subjects.

主要研究目的：评价青岛国信制药有限公司生产的罗沙司他胶囊（规格：50 mg/粒）与珐博进（中国）医药技术开发有限公司持证的罗沙司他胶囊（商品名：爱瑞卓®，规格：50 mg/粒）空腹及餐后单次口服给药在中国健康人群中的生物等效性。次要研究目的：评价受试制剂和参比制剂在中国健康成年受试者中的安全性。

[Translation]

The main purpose of the study is to evaluate the bioequivalence of rosuvastatin capsules (specification: 50 mg/capsule) produced by Qingdao Guoxin Pharmaceutical Co., Ltd. and rosuvastatin capsules (trade name: Aeridro®, specification: 50 mg/capsule) certified by FibroGen (China) Pharmaceutical Technology Development Co., Ltd., in Chinese healthy people after single oral administration on an empty stomach or after meals. Secondary purpose of the study is to evaluate the safety of the test preparation and the reference preparation in Chinese healthy adult subjects.

Start Date16 Feb 2025

Sponsor / Collaborator

Chia Tai Pharmaceutical (Qingdao) Co., Ltd.

CTR20243747

/ CompletedNot Applicable

磷酸芦可替尼片随机、开放、两周期、两序列、双交叉健康受试者空腹及餐后单次给药人体生物等效性试验

[Translation] A randomized, open-label, two-period, two-sequence, double-crossover bioequivalence study of ruxolitinib phosphate tablets in healthy subjects after single administration on an empty stomach or after a meal

主要目的：以中国健康受试者为试验对象，采用随机、开放、两周期、两序列、双交叉试验设计，考察健康受试者空腹及餐后单次口服由正大天晴药业集团股份有限公司生产（青岛国信制药有限公司持证）的磷酸芦可替尼片（受试制剂，规格：20mg，以芦可替尼计）与 Novartis Farmacéutica S.A.生产（Novartis Europharm Limited 持证）的磷酸芦可替尼片（参比制剂，商品名：Jakavi®，规格：20mg，以芦可替尼计）后芦可替尼的体内经时过程，评价空腹及餐后状态下制剂间的生物等效性。次要目的：评价磷酸芦可替尼片受试制剂和参比制剂（商品名： Jakavi®）在健康受试者中的安全性。

[Translation]

Primary objective: To investigate the in vivo time course of ruxolitinib in healthy subjects after taking a single oral dose of ruxolitinib phosphate tablets (test preparation, specification: 20 mg, calculated as ruxolitinib) produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (licensed by Qingdao Guoxin Pharmaceutical Co., Ltd.) and ruxolitinib phosphate tablets (reference preparation, trade name: Jakavi®, specification: 20 mg, calculated as ruxolitinib) produced by Novartis Farmacéutica S.A. (licensed by Novartis Europharm Limited) in fasting and postprandial state using a randomized, open, two-period, two-sequence, double-crossover design, and to evaluate the bioequivalence between the preparations in fasting and postprandial state. Secondary objective: To evaluate the safety of the test preparation and reference preparation (trade name: Jakavi®) of ruxolitinib phosphate tablets in healthy subjects.

Start Date05 Oct 2024

Sponsor / Collaborator

Chia Tai Pharmaceutical (Qingdao) Co., Ltd.

100 Clinical Results associated with Chia Tai Pharmaceutical (Qingdao) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Chia Tai Pharmaceutical (Qingdao) Co., Ltd.

Login to view more data

100 Deals associated with Chia Tai Pharmaceutical (Qingdao) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Chia Tai Pharmaceutical (Qingdao) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

1

Login to view more data